正清风痛宁定向透药联合塞来昔布治疗腰椎间盘突出症的临床疗效  

Clinical Efficacy of Zhengqing Fengtongning Directed Penetration Combined with Celecoxib in the Treatment of Lumbar Disc Herniation

作　　者：洪政茹 朱亮亮 常裕绅 匡建军[2,3] HONG Zhengru;ZHU Liangliang;CHANG Yushen;KUANG Jianjun(Hunan University of Chinese Medicine,Changsha Hunan 410208,China;The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine,Changsha Hunan 410006,China;Hunan Academy of Traditional Chinese Medicine,Changsha Hunan 410006,China)

机构地区：[1]湖南中医药大学,湖南长沙410208 [2]湖南省中医药研究院附属医院,湖南长沙410006 [3]湖南省中医药研究院,湖南长沙410006

出　　处：《中医药导报》2023年第5期99-102,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖南省自然科学基金项目(2022JJ40239);湖南省中医药研究院院级课题(202003);长沙市科技计划项目(kh2201063)。

摘　　要：目的:探讨正清风痛宁注射液定向透药联合塞来昔布治疗腰椎间盘突出症(LDH)的临床疗效。方法:将72例LDH患者按随机数字表法分为对照组和试验组,每组36例;对照组予口服塞来昔布治疗,试验组加用正清风痛宁注射液定向透药;疗程为21 d。比较治疗前后两组患者疼痛视觉模拟评分(VAS)、Oswestry功能障碍指数问卷表(ODI)评分、血清炎症因子(IL-1β、IL-6、TNF-α)水平变化,以及临床疗效。结果:治疗后,两组患者VAS评分、ODI评分均明显低于治疗前(P<0.05),两组患者血清中IL-1β、IL-6、TNF-α水平均低于治疗前(P<0.05),且试验组患者VAS评分、ODI评分均高于对照组(P<0.05),试验组患者血清中IL-1β、IL-6、TNF-α水平均低于对照组(P<0.05)。试验组总有效率为94.44%(34/36),高于对照组的75.00%(27/36),差异有统计学意义(P<0.05)。结论:正清风痛宁注射液定向透药联合塞来昔布可显著改善LDH患者VAS评分、ODI评分,降低血清炎症因子水平,改善患者腰痛的症状,提高LDH患者生活质量。Objective:To investigate the clinical efficacy of Zhengqing Fengtongning directed penetration combined with Celecoxib in lumbar disc herniation(LDH).Methods:A total of 72 LDH patients were divided into control and treatment groups according to random number table method,with 36 patients in each group.The control group was treated with oral Celecoxib.The treatment group was treated with Zhengqing Fengtongning directed penetration.The course of treatment was 21 days.The VAS score,ODI score and serum inflammatory factors(IL-1β,IL-6,TNF-α)were compared before and after treatment.Results:After treatment,the VAS score and ODI score were lower than those before treatment in two groups(P<0.05),and the levels of serum IL-1β,IL-6 and TNF-αwere lower hose before treatment in two groups(P<0.05).The treatment group showed lower VAS score and ODI score than control group after treatment(P<0.05),and treatment group showed lower levels of serum IL-1β,IL-6 and TNF-αthan control group after treatment(P<0.05).Conclusions:Zhengqing Fengtongning targeted transdermal drug delivery combined with Celecoxib can significantly improve the VAS score and ODI score of LDH patients,reduce the content of serum inflammatory factors,improve the symptoms of low back pain,and increase the quality of life of LDH patients.

关 键 词：腰椎间盘突出症 正清风痛宁注射液 塞来昔布 中医定向透药 临床疗效 

分 类 号：R274.33[医药卫生—中医骨伤科学]